Leerink Partners Begins Coverage on AgomAb Therapeutics (NASDAQ:AGMB)

Analysts at Leerink Partners assumed coverage on shares of AgomAb Therapeutics (NASDAQ:AGMB) in a note issued to investors on Tuesday, MarketBeat Ratings reports. The brokerage set an “outperform” rating and a $36.00 price target on the stock. Leerink Partners’ target price points to a potential upside of 145.23% from the company’s current price.

A number of other equities analysts have also recently issued reports on AGMB. Morgan Stanley initiated coverage on shares of AgomAb Therapeutics in a research report on Tuesday. They set an “overweight” rating and a $28.00 price objective for the company. Wall Street Zen raised shares of AgomAb Therapeutics to a “hold” rating in a research report on Tuesday, February 17th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $32.00.

AgomAb Therapeutics Stock Down 7.7%

Shares of NASDAQ:AGMB opened at $14.68 on Tuesday. AgomAb Therapeutics has a 1 year low of $12.66 and a 1 year high of $17.45.

More AgomAb Therapeutics News

Here are the key news stories impacting AgomAb Therapeutics this week:

• Positive Sentiment: Major brokerages initiated or reiterated bullish coverage with high price targets that imply large upside vs. the current price — JPMorgan started coverage at “Overweight” with a $32 PT (~+118%). JPMorgan Coverage
• Positive Sentiment: Leerink Partners initiated coverage at “Outperform” with a $36 price target (~+145%), which could attract momentum buying from institutional investors. Leerink Coverage (Benzinga) Leerink Coverage (Zacks)
• Positive Sentiment: Morgan Stanley initiated coverage at “Overweight” with a $28 price target (~+91%), reinforcing analyst-driven upside expectations across the sell-side. Morgan Stanley Coverage
• Neutral Sentiment: Short-interest reports posted large increases in “short interest” for early March, but the published figures are internally inconsistent (showing 0 shares and NaN changes); the data appears unreliable and provides no clear signal on actual short pressure. Investors should treat these short-interest entries with caution until corrected filings are available.

AgomAb Therapeutics Company Profile

AgomAb Therapeutics (NASDAQ: AGMB) is a biotechnology company focused on the discovery and development of monoclonal antibody therapeutics. The company’s name and stated strategy center on the creation of agonist antibodies designed to modulate specific receptor pathways, with the aim of providing disease-modifying treatments where conventional approaches have been limited. AgomAb’s work spans early-stage discovery through translational development and regulatory-directed studies.

AgomAb’s activities include antibody engineering, target validation, and progression of programs through preclinical and, when applicable, clinical development milestones.